NK-3 receptor antagonism prevents behavioral sensitization to cocaine: a role of glycogen synthase kinase-3 in the nucleus accumbens.
Repeated administration of cocaine induces heightened behavioral hyperactivity termed sensitization. Although NK-3 receptors have been shown to modulate acute cocaine-induced behaviors, their role in behavioral sensitization is unknown. The present study investigated whether NK-3 receptor blockade altered behavioral sensitization to cocaine. Additionally, glycogen synthase kinase-3 (GSK3) has been shown to be involved in dopamine receptor signaling and in development of sensitization; therefore regulation of GSK3 activity in the nucleus accumbens was also investigated. Administration of the NK-3 receptor antagonist SB 222200 (5 mg/kg, s.c.) prior to repeated cocaine (20 mg/kg, i.p.) prevented the development of sensitized responses after a cocaine challenge. Pre-treatment with SB 222200 before a cocaine challenge also blocked expression of sensitization. Decrease in GSK3 activity demonstrated by increased phosphorylation of GSK3α and GSK3β was detected 20 mins after an acute cocaine injection. In contrast, a cocaine challenge failed to alter phosphorylation of GSK3α and GSK3β in sensitized mice. SB 222200 prior to repeated cocaine resulted in increased phosphorylation of GSK3α and GSK3β akin to changes following acute cocaine. Collectively, these findings demonstrate the involvement of NK-3 receptors in development and expression of behavioral sensitization and in regulation of GSK3 activity in the nucleus accumbens after repeated cocaine.
Nwaneshiudu
Chinwe A
CA
Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA. cnwanesh@temple.edu
Unterwald
Ellen M
EM
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D003042:Cocaine / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D038362:Glycogen Synthase Kinase 3 / Q000502:physiology*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009714:Nucleus Accumbens / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D010766:Phosphorylation; D011804:Quinolines / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000502:physiology; D018042:Receptors, Neurokinin-3 / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000502:physiology
D018765:Dopamine Uptake Inhibitors; D011804:Quinolines; D011954:Receptors, Dopamine; D018042:Receptors, Neurokinin-3; C109112:SB 222200; D038362:Glycogen Synthase Kinase 3; D003042:Cocaine; D004298:Dopamine
FEBS Lett. 1996 Dec 16;399(3):333-8
8985174
Neuropharmacology. 2009 Jun;56(8):1116-23
19328817
Brain Res. 1995 Oct 9;695(1):19-24
8574643
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
2899326
Brain Res Brain Res Rev. 1991 Sep-Dec;16(3):223-44
1665095
Synapse. 1993 Aug;14(4):314-23
8161369
Neuropharmacology. 2009 Sep;57(3):295-301
19500601
Neuroscience. 1989;32(2):323-35
2479882
Prog Neurobiol. 2001 Nov;65(4):391-426
11527574
J Pharmacol Exp Ther. 2000 Oct;295(1):373-81
10992004
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5099-104
15044694
Eur J Pharmacol. 1996 Dec 27;318(1):31-5
9007509
J Pharmacol Exp Ther. 1996 Aug;278(2):490-502
8768696
Neuron. 2000 Mar;25(3):515-32
10774721
Eur J Neurosci. 2007 Apr;25(8):2457-72
17445241
Pharmacol Biochem Behav. 1981 Oct;15(4):559-62
7197373
Neuropeptides. 1998 Oct;32(5):481-8
9845011
Mol Cell Biol. 2000 Dec;20(24):9356-63
11094086
J Comp Neurol. 1988 Jun 1;272(1):90-113
2454979
Science. 2003 Nov 21;302(5649):1412-5
14631045
Eur J Neurosci. 1999 May;11(5):1598-604
10215912
Neuropharmacology. 1993 Apr;32(4):387-91
8497339
Brain Res Brain Res Rev. 1997 Oct;25(2):192-216
9403138
J Neurochem. 2009 Dec;111(6):1357-68
19799712
Neuropsychopharmacology. 2005 Aug;30(8):1443-54
15770241
J Comp Neurol. 1992 Mar 22;317(4):341-56
1374442
Br J Pharmacol. 1992 Jan;105(1):3-5
1375857
Eur J Pharmacol. 1991 Mar 19;195(1):107-14
1712305
J Neurochem. 2008 Mar;104(6):1440-9
18221378
J Neurochem. 2007 Oct;103(2):706-13
17635666
Commun Psychopharmacol. 1979;3(5):285-90
575770
J Pharmacol Exp Ther. 1998 Sep;286(3):1171-6
9732375
Neuropharmacology. 2009;56 Suppl 1:160-8
18657553
J Neurosci. 2006 Aug 30;26(35):9022-9
16943560
Am J Addict. 2001 Summer;10(3):201-17
11579619
J Pharmacol Exp Ther. 1994 Sep;270(3):1387-96
7932193
Eur J Pharmacol. 1992 Mar 17;213(1):165-6
1379929
Science. 1987 Sep 4;237(4819):1219-23
2820058
Brain Res. 2004 Oct 8;1023(1):126-33
15364027
Addiction. 2001 Jan;96(1):103-14
11177523
J Neurosci. 2002 Oct 15;22(20):8911-21
12388598
Nature. 1976 Apr 22;260(5553):731-2
944382
Psychopharmacology (Berl). 2000 Aug;151(2-3):99-120
10972458
J Neurosci. 2002 Jul 15;22(14):5817-22
12122043
Pharmacol Ther. 2005 Jun;106(3):389-403
15922019
Ann N Y Acad Sci. 1990;579:254-72
2159744
Neuroscience. 2001;102(4):843-51
11182247
J Pharmacol Exp Ther. 1997 May;281(2):699-706
9152375
Eur J Pharmacol. 2006 May 1;536(3):269-78
16603151
J Psychopharmacol. 1998;12(1):49-53
9584968
Eur J Neurosci. 2006 Sep;24(6):1721-32
17004936
Brain Res Bull. 2010 May 31;82(3-4):184-7
20347018
Brain Res Mol Brain Res. 1998 Feb;54(1):141-51
9526067
Peptides. 2006 Sep;27(9):2214-23
16621146
J Pharmacol Exp Ther. 1991 Sep;258(3):882-90
1890623
J Biol Chem. 1951 Nov;193(1):265-75
14907713